ECSP20003147A - Carboxamidas como moduladores de los canales de sodio - Google Patents

Carboxamidas como moduladores de los canales de sodio

Info

Publication number
ECSP20003147A
ECSP20003147A ECSENADI20203147A ECDI202003147A ECSP20003147A EC SP20003147 A ECSP20003147 A EC SP20003147A EC SENADI20203147 A ECSENADI20203147 A EC SENADI20203147A EC DI202003147 A ECDI202003147 A EC DI202003147A EC SP20003147 A ECSP20003147 A EC SP20003147A
Authority
EC
Ecuador
Prior art keywords
carboxamides
modulators
sodium channels
compounds
pharmaceutically acceptable
Prior art date
Application number
ECSENADI20203147A
Other languages
English (en)
Inventor
Joanne Louise Camp
Meireles Lidio Marx Carvalho
Patel Urvi
Yvonne Schmidt
Lev Tyler Fanning
Corey Anderson
Vijayalaksmi Arumugam
Nadia Ahmad
Iuliana Luci Asgian
Stephen Thomson
Ruah Sara Hadida
David Shaw
Dennis Hurley
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ECSP20003147A publication Critical patent/ECSP20003147A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)

Abstract

Se proporcionan compuestos y sus sales farmacéuticamente aceptables, de utilidad como inhibidores de canales de sodio. Además, se proporcionan composiciones farmacéuticas que comprenden los compuestos o sales farmacéuticamente aceptables y métodos de uso de los compuestos, sales farmacéuticamente aceptables y composiciones farmacéuticas en el tratamiento de varios trastornos, incluyendo dolor.
ECSENADI20203147A 2017-07-11 2020-01-15 Carboxamidas como moduladores de los canales de sodio ECSP20003147A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531313P 2017-07-11 2017-07-11
US201762608283P 2017-12-20 2017-12-20
PCT/US2018/041649 WO2019014352A1 (en) 2017-07-11 2018-07-11 CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS

Publications (1)

Publication Number Publication Date
ECSP20003147A true ECSP20003147A (es) 2020-02-28

Family

ID=63036498

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20203147A ECSP20003147A (es) 2017-07-11 2020-01-15 Carboxamidas como moduladores de los canales de sodio

Country Status (23)

Country Link
US (3) US10647661B2 (es)
EP (1) EP3651752A1 (es)
JP (1) JP7277431B2 (es)
KR (1) KR20200026987A (es)
CN (1) CN111065383A (es)
AU (1) AU2018300150A1 (es)
BR (1) BR112020000553A2 (es)
CA (1) CA3069720A1 (es)
CL (1) CL2020000075A1 (es)
CO (1) CO2020000145A2 (es)
CR (1) CR20200064A (es)
DO (1) DOP2020000004A (es)
EC (1) ECSP20003147A (es)
IL (1) IL271948A (es)
JO (1) JOP20200001A1 (es)
MA (1) MA49566A (es)
PE (1) PE20201164A1 (es)
PH (1) PH12020500066A1 (es)
SG (1) SG11202000230VA (es)
TN (1) TN2020000001A1 (es)
TW (1) TW201920081A (es)
UY (1) UY37806A (es)
WO (1) WO2019014352A1 (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11866450B2 (en) 2018-02-15 2024-01-09 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
US11873300B2 (en) 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
US12122788B2 (en) 2023-01-04 2024-10-22 Vertex Pharmaceuticals Incorporated Process of making CFTR modulators

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35288A (es) 2013-01-31 2014-08-29 Vertex Pharma Piridonamidas como moduladores de canales de sodio
CA2918365C (en) 2013-07-19 2021-09-07 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
SG11201604477SA (en) 2013-12-13 2016-07-28 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
WO2018213426A1 (en) 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
JOP20200001A1 (ar) 2017-07-11 2022-10-30 Vertex Pharma كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
EP3752152A1 (en) 2018-02-12 2020-12-23 Vertex Pharmaceuticals Incorporated A method of treating pain
EP3820866A4 (en) * 2018-07-09 2022-04-06 Lieber Institute, Inc. PYRIDINE CARBOXAMIDE COMPOUNDS TO INHIBIT NAV1.8
JP2021531256A (ja) 2018-07-09 2021-11-18 リーバー インスティチュート インコーポレイテッドLieber Institute, Inc. ＮａＶ１．８を阻害するピリダジン化合物
BR112021008524A8 (pt) * 2018-11-02 2023-02-07 Merck Sharp & Dohme 2-amino-n-heteroaril-nicotinamidas como inibidores de nav 1.8
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US20220110923A1 (en) * 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
TW202043200A (zh) * 2019-01-25 2020-12-01 大陸商江蘇恆瑞醫藥股份有限公司 ２－側氧基－１，２－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
WO2021032074A1 (zh) * 2019-08-19 2021-02-25 江苏恒瑞医药股份有限公司 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用
CN118146148A (zh) * 2019-09-12 2024-06-07 上海济煜医药科技有限公司 吡啶氮氧化合物及其制备方法和用途
CN110950797A (zh) * 2019-12-06 2020-04-03 丽水绿氟科技有限公司 一种2-三氟甲基-3-氟-4-吡啶甲酸及其衍生物的制备方法
TW202128675A (zh) * 2019-12-06 2021-08-01 美商維泰克斯製藥公司 作為鈉通道調節劑之經取代四氫呋喃
CN110937994B (zh) * 2019-12-10 2022-04-22 浙江大洋生物科技集团股份有限公司 二步氯化法合成2,4-二氯-6-氟苯甲酰氯的方法
CN114437062B (zh) * 2020-04-30 2024-05-17 成都海博为药业有限公司 一种可作为钠通道调节剂的化合物及其用途
US20230348392A1 (en) 2020-05-06 2023-11-02 Bayer Aktiengesellschaft Pyridine (thio)amides as fungicidal compounds
US20230180756A1 (en) 2020-05-12 2023-06-15 Bayer Aktiengesellschaft Triazine and pyrimidine (thio)amides as fungicidal compounds
JP7323723B2 (ja) 2020-06-17 2023-08-08 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド
CN113880771B (zh) * 2020-07-03 2023-09-19 福建盛迪医药有限公司 一种选择性Nav抑制剂的结晶形式及其制备方法
CN111920796A (zh) * 2020-08-28 2020-11-13 南京医科大学 化合物在制备治疗癫痫药物中的应用
CN111808019B (zh) * 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
CN114031518B (zh) * 2020-12-08 2023-08-18 成都海博为药业有限公司 一种苄胺或苄醇衍生物及其用途
TW202300147A (zh) 2021-03-11 2023-01-01 大陸商上海濟煜醫藥科技有限公司 吡啶氮氧化合物晶型及其應用
AU2022253450A1 (en) 2021-04-05 2023-11-16 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
MX2023013146A (es) 2021-05-07 2023-11-28 Merck Sharp & Dohme Llc Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
CN117794919A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺类似物作为钠通道调节剂
IL308934A (en) * 2021-06-04 2024-01-01 Vertex Pharma Manufacturing process of converted natran tetrahydrofuran channel modulators
CA3221788A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CA3221960A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
PE20241335A1 (es) 2021-06-04 2024-07-03 Vertex Pharma N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
KR20240031299A (ko) 2021-06-04 2024-03-07 버텍스 파마슈티칼스 인코포레이티드 (2r,3s,4s,5r)-4-[[3-(3,4-디플루오로-2-메톡시-페닐)-4,5-디메틸-5-(트리플루오로메틸)테트라하이드로푸란-2-카르보닐]아미노]피리딘-2-카르복사미드를 포함하는 고체 투여 형태 및 투여 요법
CA3221938A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
AR126670A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
AR126669A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
CN116462662A (zh) 2022-01-18 2023-07-21 成都康弘药业集团股份有限公司 芳香并环类Nav1.8抑制剂及其用途
WO2023186102A1 (zh) * 2022-04-02 2023-10-05 武汉人福创新药物研发中心有限公司 Nav1.8抑制剂及其用途
TW202404969A (zh) 2022-04-22 2024-02-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023207949A1 (zh) * 2022-04-25 2023-11-02 中国科学院上海药物研究所 并环类化合物及其应用
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
TW202413335A (zh) * 2022-06-22 2024-04-01 大陸商武漢人福創新藥物研發中心有限公司 Ｎａｖ１．８抑制劑
WO2024041613A1 (zh) * 2022-08-24 2024-02-29 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用
WO2024046253A1 (zh) * 2022-08-28 2024-03-07 上海汇伦医药股份有限公司 一种钠通道调节剂及其应用
WO2024046409A1 (zh) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用
WO2024054622A2 (en) * 2022-09-09 2024-03-14 Latigo Biotherapeutics, Inc. Sodium channel blocking compounds, derivatives thereof, and methods of their use
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
WO2024146632A1 (zh) * 2023-01-06 2024-07-11 西藏海思科制药有限公司 一种四氢噻吩衍生物及其在医药上的应用
WO2024153856A1 (en) * 2023-01-18 2024-07-25 Orion Corporation Process for the preparation of 3-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)pyridine 1-oxide

Family Cites Families (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1025305A (en) 1910-07-29 1912-05-07 Andrew Rasmussen Feeding means for power hacksaw-machines.
US1008714A (en) 1910-12-27 1911-11-14 Henry M Hammer Delinting-machine.
US2511231A (en) 1949-03-26 1950-06-13 Eastman Kodak Co 1-cyanophenyl-3-acylamino-5-pyrazolone couplers for color photography
US2688617A (en) 1951-07-17 1954-09-07 American Cyanamid Co Sulfonated dihalogeno diaminostilbenes
BE516025A (es) 1951-12-05
US2657134A (en) 1951-12-05 1953-10-27 Eastman Kodak Co Photographic emulsion with colored couplers containing isophthalic ester groups
US2725292A (en) 1952-05-15 1955-11-29 Eastman Kodak Co Colored couplers containing solubilizing groups
US2710802A (en) 1953-03-16 1955-06-14 Eastman Kodak Co Dialkyl-5-(oxanilamido) isophthalate couplers for color photography
US2710803A (en) 1953-03-26 1955-06-14 Eastman Kodak Co Color couplers containing hydroxyalkyl groups
BE528163A (es) 1953-04-17
BE531589A (es) 1953-09-02
US4218765A (en) 1974-10-03 1980-08-19 Standard Oil Company (Indiana) Two-dimensional frequency domain filtering
DE2623228C3 (de) 1976-05-24 1981-09-10 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren N-Acyl-substituierte Benzamide, Verfahren zu ihrer Herstellung und Arzneimittel, enthaltend solche Benzamide
US4639273A (en) 1983-05-06 1987-01-27 Morton Thiokol, Inc. Asphalt-adhesion improving additives prepared by formaldehyde condensation with polyamines
JPS63182182A (ja) 1987-01-23 1988-07-27 Fuji Photo Film Co Ltd 感熱記録材料
FR2628864B1 (fr) 1988-03-21 1990-06-15 France Etat Procede de segmentation d'un champ de vecteurs vitesse, notamment de vitesses de deplacement de points d'une image dans une sequence d'images
KR920701167A (ko) 1989-07-07 1992-08-11 에릭 에스. 딕커 약제학적 활성 화합물
JP2766323B2 (ja) 1989-07-19 1998-06-18 株式会社東芝 表示調整装置
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
DE4019307A1 (de) 1990-06-16 1991-12-19 Bayer Ag 2-methoximinocarbonsaeureester
US5449691A (en) 1991-12-31 1995-09-12 Sterling Winthrop Inc. 3,4-disubstituted anilines-immunomodulating agents
US5258407A (en) 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
FR2687932A1 (fr) 1992-02-27 1993-09-03 Oreal Dispersion huile-dans-l'eau susceptible de former des films composites.
JPH05313169A (ja) 1992-05-08 1993-11-26 Fuji Photo Film Co Ltd 液晶配向膜
HUT63941A (en) 1992-05-15 1993-11-29 Hoechst Ag Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
GB9408185D0 (en) 1994-04-25 1994-06-15 Fujisawa Pharmaceutical Co New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
CN1048239C (zh) 1994-05-31 2000-01-12 帝人株式会社 萘衍生物
US5532235A (en) 1995-01-17 1996-07-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5536718A (en) 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE19523640A1 (de) 1995-06-29 1997-01-02 Bayer Ag Substituierte Carbonylaminophenyluracile
DE19621522A1 (de) 1996-05-29 1997-12-04 Hoechst Schering Agrevo Gmbh Neue N-Acylsulfonamide, neue Mischungen aus Herbiziden und Antidots und deren Verwendung
JP3731963B2 (ja) 1997-01-14 2006-01-05 株式会社シマノ 釣り竿用口栓
JPH10213820A (ja) 1997-01-31 1998-08-11 Canon Inc 液晶素子及び液晶装置
DK0977741T3 (da) 1997-04-22 2003-12-01 Neurosearch As Substituerede phenylderivater, deres fremstilling og anvendelse
JP2002506873A (ja) 1998-03-18 2002-03-05 アリアド・ファーマシューティカルズ・インコーポレイテッド 複素環式シグナル伝達阻害剤、それを含む組成物
AU3665199A (en) 1998-04-29 1999-11-16 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
JP2002179651A (ja) 1998-06-19 2002-06-26 Wakamoto Pharmaceut Co Ltd ベンズアニリド誘導体及び医薬組成物
EP1514867A3 (en) 1998-10-22 2005-03-23 NeuroSearch A/S Substituted phenyl derivatives, their preparation and use
JP2002543065A (ja) 1999-04-28 2002-12-17 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｐ受容体リガンドとしてのトリアリール酸誘導体
AU6228000A (en) 1999-07-23 2001-02-13 Allergan Sales, Inc. The use of retinoid receptor antagonists in the treatment of prostate carcinoma
WO2001019788A2 (en) 1999-09-17 2001-03-22 Cor Therapeutics, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
US6531291B1 (en) 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
WO2001056989A2 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. Inhibitors of factor xa
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
NZ521225A (en) 2000-03-09 2004-08-27 Aventis Pharma Gmbh Therapeutic uses of PPAR mediators
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
DE10033337A1 (de) 2000-07-08 2002-01-17 Boehringer Ingelheim Pharma Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1326835A1 (en) 2000-10-05 2003-07-16 Fujisawa Pharmaceutical Co., Ltd. Benzamide compounds as apo b secretion inhibitors
IL155202A0 (en) 2000-10-20 2003-11-23 Biocryst Pharm Inc Biaryl compounds as serine protease inhibitors
EP1332131A2 (en) 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
WO2002044179A1 (fr) 2000-11-28 2002-06-06 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de 1,4,5,6-tétrahydroimidazo[4,5-d]diazépine ou sels de ces derniers
RU2003120070A (ru) 2000-12-06 2004-12-27 Авентис Фармаа Дойчланд Гмбх (De) Производные гуанидина и амидина в качестве ингибиторов фактора ха
CN1289072C (zh) 2000-12-22 2006-12-13 石原产业株式会社 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2002054077A2 (en) 2000-12-29 2002-07-11 7Tm Pharma A/S Validating biological molecules as drug targets by metal-ion chelates in animal test models
WO2002070483A1 (en) 2001-03-05 2002-09-12 E. I. Du Pont De Nemours And Company Heterocyclic diamide invertebrate pest control agents
JP4342178B2 (ja) 2001-04-06 2009-10-14 バイオクリスト・ファマシューティカルズ インク． セリンプロテアーゼ阻害剤としてのビアリール化合物
US20040157866A1 (en) 2001-04-30 2004-08-12 Hisashi Takasugi Amide compounds
WO2002098839A1 (fr) 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamides et procede de preparation de ceux-ci
WO2002101007A2 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc Antipathogenic benzamide compounds
WO2003003009A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Use of metal-ion chelates in validating biological molecules as drug targets in test animal models
WO2003003008A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Chemical libraries useful for drug discovery processes
DE10132686A1 (de) 2001-07-05 2003-01-16 Boehringer Ingelheim Pharma Heteroarylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
US20030130343A1 (en) 2001-08-10 2003-07-10 Adipogenix, Inc. Fat accumulation-modulating compounds
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US20050038035A1 (en) 2001-11-28 2005-02-17 Hisashi Takasugi Heterocyclic amide compounds as apolipoprotein b inhibitors
AU2002367087A1 (en) 2001-12-21 2003-07-15 7Tm Pharma A/S Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
AU2003205570A1 (en) 2002-01-10 2003-07-24 Boehringer Ingelheim Pharma Gmbh And Co. Kg Combination of mtp inhibitors or apob secretion inhibitors with fibrates for use as drugs
JP2005516037A (ja) 2002-01-22 2005-06-02 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー ジアミド無脊椎有害生物防除剤
NZ531890A (en) 2002-02-28 2006-02-24 Japan Tobacco Inc Ester compound and medicinal use thereof
PL373030A1 (en) 2002-03-11 2005-08-08 Tibotec Pharmaceuticals Ltd. Small molecule entry inhibitors
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
JP2003342175A (ja) 2002-05-24 2003-12-03 Yamanouchi Pharmaceut Co Ltd 新規なベンゾアゼピン誘導体又はその塩を有効成分とするメニエール病治療剤
JP2004043456A (ja) 2002-05-24 2004-02-12 Yamanouchi Pharmaceut Co Ltd ベンゾアゼピン誘導体又はその塩を有効成分とする医薬
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
AU2003265398A1 (en) 2002-08-09 2004-02-25 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
JP2004175739A (ja) 2002-11-28 2004-06-24 Tanabe Seiyaku Co Ltd 医薬組成物
EP1569893B1 (en) 2002-12-12 2012-04-11 Basf Se Amino substituted hydroxyphenyl benzophenone derivatives
MXPA05006744A (es) 2002-12-20 2005-09-08 Pfizer Prod Inc Inhibidores de la proteina microsomal de transferencia de trigliceridos.
KR101145252B1 (ko) 2003-01-08 2012-05-24 유니버시티 오브 워싱톤 항균제
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
JP2004315395A (ja) 2003-04-14 2004-11-11 Yamanouchi Pharmaceut Co Ltd 新規な安息香酸誘導体又はその塩
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
WO2005033079A1 (ja) 2003-09-30 2005-04-14 Eisai Co., Ltd. ヘテロ環化合物を含有する新規な抗真菌剤
EP1679309A4 (en) 2003-10-24 2007-03-28 Ono Pharmaceutical Co ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
KR100857312B1 (ko) 2004-01-28 2008-09-05 미쓰이 가가쿠 가부시키가이샤 아미드 유도체 및 그 제조 방법 및 그의 살충제로서의 사용 방법
DE102004009238A1 (de) 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
US7427390B2 (en) 2004-03-10 2008-09-23 Schering Ag Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
WO2006007864A1 (en) 2004-07-17 2006-01-26 Max Planck Geselllschaft Zur Förderung Der Wissenschaft Treating neurodegenerative conditions
US7649004B2 (en) 2004-07-23 2010-01-19 Pfizer, Inc. Pyridine derivatives
DE102004050196A1 (de) 2004-10-15 2006-04-20 Sanofi-Aventis Deutschland Gmbh Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
AU2005311251A1 (en) 2004-12-01 2006-06-08 Devgen Nv 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the Kv family
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
US8067638B2 (en) 2005-06-21 2011-11-29 Mitsui Chemicals, Inc. Amide derivative and insecticide containing the same
MX2007016070A (es) 2005-07-07 2008-03-10 Abbott Lab Promotores de apoptosis.
JP4580836B2 (ja) 2005-07-25 2010-11-17 三井化学アグロ株式会社 殺虫殺菌組成物
AU2006287521A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. PPARactive compounds
EP1942732A2 (en) 2005-11-02 2008-07-16 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
US20090306102A1 (en) 2005-12-20 2009-12-10 Eriksen Birgitte L 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
US7351434B2 (en) 2006-04-07 2008-04-01 Academia Sinica Therapeutic Gastrodia extracts
MX2008013194A (es) 2006-04-11 2008-12-01 Vertex Pharma Composiciones utiles como inhibidores de canales de sodio regulados por voltaje.
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
US20090325956A1 (en) 2006-10-13 2009-12-31 Takahiko Taniguchi Aromatic amine derivative and use thereof
JP2008106017A (ja) 2006-10-27 2008-05-08 Tokyo Univ Of Science Ｏａｔｐ選択的阻害性を有する化合物、及び該化合物を含むｏａｔｐの選択的阻害剤
PT2101760E (pt) 2006-12-08 2013-05-07 Millennium Pharm Inc Formulações de dose unitária e métodos de tratamento da trombose com um inibidor oral do fator xa
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP4325681B2 (ja) 2007-02-13 2009-09-02 ソニー株式会社 固体撮像装置、撮像装置
CN101622231B (zh) 2007-02-28 2013-12-04 艾德维纳斯医疗私人有限公司 作为葡糖激酶激活剂的2，2，2-三取代的乙酰胺衍生物、它们的制造方法和药学应用
JP4657384B2 (ja) 2007-05-03 2011-03-23 ファイザー・リミテッド ナトリウムチャンネルモジュレーターとしての２−ピリジンカルボキサミド誘導体
WO2008140810A1 (en) 2007-05-11 2008-11-20 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008156783A2 (en) 2007-06-18 2008-12-24 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities
MX2009013753A (es) 2007-06-26 2010-01-26 Sanofi Aventis Una sintesis regioselectiva catalizada por cobre de bencimidazoles y azabencimidazoles.
US20090012091A1 (en) 2007-07-02 2009-01-08 Kinagen, Inc. Oximide derivatives and their therapeutical application
JP5473921B2 (ja) 2007-10-10 2014-04-16 ビーエーエスエフ ソシエタス・ヨーロピア スルホニウム塩開始剤
WO2009047105A1 (en) 2007-10-10 2009-04-16 Basf Se Sulphonium salt initiators
CA2701946A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
US8389734B2 (en) 2007-10-11 2013-03-05 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
CA2702101A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
JP2009108152A (ja) 2007-10-29 2009-05-21 Sumitomo Chemical Co Ltd 重合性化合物および光学フィルム
WO2009070533A1 (en) 2007-11-29 2009-06-04 Complegen, Inc. Methods of inhibiting steroyl coa desaturase
JP2009149754A (ja) 2007-12-20 2009-07-09 Sumitomo Chemical Co Ltd 重合性化合物および該重合性化合物を重合してなる光学フィルム
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP2009209090A (ja) 2008-03-04 2009-09-17 Mitsui Chemicals Inc 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法
US20100009970A1 (en) 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
JP5219583B2 (ja) 2008-03-31 2013-06-26 住友化学株式会社 組成物、光学フィルムとその製造方法、光学部材及び表示装置
JP2010001284A (ja) 2008-05-20 2010-01-07 Sumitomo Chemical Co Ltd 化合物及び光学フィルム
PT2959900T (pt) 2008-06-16 2017-06-22 Univ Tennessee Res Found Composto para tratamento do cancro
BRPI0917936A2 (pt) 2008-08-25 2017-07-11 Irm Llc Moduladores de via hedgehog
JP5443720B2 (ja) 2008-09-05 2014-03-19 住友化学株式会社 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置
JP2010066630A (ja) 2008-09-12 2010-03-25 Sumitomo Chemical Co Ltd 光学フィルムの製造方法及び光学フィルム
PT2340021E (pt) 2008-09-18 2013-01-25 Hoffmann La Roche Pirrolidino-2-carboxamidas substituídas
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP5649779B2 (ja) 2008-11-28 2015-01-07 住友化学株式会社 液晶性組成物及び光学フィルム
US8471038B2 (en) 2008-12-26 2013-06-25 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic heterocyclic compound
CN101838264B (zh) 2009-03-16 2014-12-03 住友化学株式会社 化合物、光学膜和光学膜的制造方法
JP5899607B2 (ja) 2009-03-16 2016-04-06 住友化学株式会社 化合物、光学フィルム及び光学フィルムの製造方法
AR076880A1 (es) 2009-05-18 2011-07-13 Orion Corp Inhibidores de proteasa, composiciones farmaceuticas que los contienen y su uso.
EP2253617A1 (de) 2009-05-20 2010-11-24 Bayer CropScience AG Halogen-substituierte Verbindungen als Pestizide
WO2010138901A1 (en) 2009-05-29 2010-12-02 Biogen Idec Ma Inc Carboxylic acid-containing compounds, derivatives thereof, and related methods of use
JP2011006360A (ja) 2009-06-26 2011-01-13 Sumitomo Chemical Co Ltd 化合物、光学フィルム及び光学フィルムの製造方法
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8629149B2 (en) 2009-09-04 2014-01-14 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
CA2773561A1 (en) 2009-09-14 2011-03-17 Phusis Therapeutics Inc. Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
US8420647B2 (en) 2010-01-21 2013-04-16 Hoffmann-La Roche Inc. 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds
JP5375644B2 (ja) 2010-02-10 2013-12-25 住友化学株式会社 組成物及び光学フィルム
CN102883607B (zh) 2010-03-01 2015-07-22 Gtx公司 用于治疗癌的化合物
JP2013525368A (ja) 2010-04-23 2013-06-20 キネタ・インコーポレイテツド 抗ウイルス性化合物
US8754219B2 (en) 2010-04-27 2014-06-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
HUE028983T2 (en) 2010-05-06 2017-01-30 Vertex Pharma Heterocyclic chromene-spirocyclic piperidine amides as ion channel modulators
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US20130158035A1 (en) 2010-08-24 2013-06-20 Brigham Young University Antimetastatic compounds
WO2012026931A1 (en) 2010-08-25 2012-03-01 Synta Pharmaceuticals Corp. Method of synthesizing substituted 2-alkyl phenols
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
EP3056495A1 (en) 2011-02-02 2016-08-17 Vertex Pharmaceuticals Inc. Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
US10385070B2 (en) 2011-02-18 2019-08-20 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
WO2012125613A1 (en) 2011-03-14 2012-09-20 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US9278910B2 (en) 2011-05-31 2016-03-08 Receptos, Inc. GLP-1 receptor stabilizers and modulators
JP2014520151A (ja) 2011-06-20 2014-08-21 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 蠕虫感染を処置するためのヘテロ環式化合物
AU2012275841A1 (en) 2011-06-27 2014-01-16 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
US9169246B2 (en) 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
ES2527188T3 (es) 2011-09-26 2015-01-21 Sanofi Derivados de pirazolquinolinona, su preparación y su uso terapéutico
CN103012397B (zh) 2011-09-26 2017-03-01 赛诺菲 吡唑并喹啉酮衍生物、其制备方法及其治疗用途
PE20141682A1 (es) 2011-10-26 2014-11-14 Pfizer Ltd Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
GB201119799D0 (en) 2011-11-16 2011-12-28 Sentinel Oncology Ltd Pharmaceutical compounds
EP2788332A1 (en) 2011-12-07 2014-10-15 Amgen, Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
EP2606726A1 (de) 2011-12-21 2013-06-26 Bayer CropScience AG N-Arylamidine-substituierte trifluoroethylsulfid-Derivate als Akarizide und Insektizide
US20140357633A1 (en) 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
US9403839B2 (en) 2012-01-16 2016-08-02 Vertex Pharmaceuticals Incorporated Pyran-spirocyclic piperidine amides as modulators of ion channels
CA2861439C (en) 2012-02-03 2016-07-12 Pfizer Inc. Benzimidazole and imidazopyridine derivatives as sodium channel modulators
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
US8481479B1 (en) 2012-03-07 2013-07-09 Shaker A. Mousa Formulations of factor VIIa inhibitors and utility
US8980823B2 (en) 2012-03-07 2015-03-17 Shaker A. Mousa Formulations of Factor VIIa inhibitors and utility
US20150210717A1 (en) 2012-09-13 2015-07-30 Baden-Württemberg Stiftung Gmbh Specific inhibitors of protein p21 as therapeutic agents
WO2014055634A1 (en) 2012-10-02 2014-04-10 Yale University Identification of small molecule inhibitors of jumonji at-rich interactive domain 1a (jarid1a) and 1b (jarid1b) histone demethylase
US9216180B2 (en) 2012-10-02 2015-12-22 New York University Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated RNA decay
US20140200215A1 (en) 2013-01-15 2014-07-17 Intermune, Inc. Lysophosphatidic acid receptor antagonists
UY35288A (es) 2013-01-31 2014-08-29 Vertex Pharma Piridonamidas como moduladores de canales de sodio
ES2620379T3 (es) 2013-01-31 2017-06-28 Vertex Pharmaceuticals Inc. Quinolina y quinoxalina amidas como moduladores de canales de sodio
SG11201505954RA (en) 2013-01-31 2015-08-28 Vertex Pharma Amides as modulators of sodium channels
CN103961348B (zh) 2013-02-05 2016-08-17 上海交通大学医学院 Senp1小分子抑制剂及其应用
US9580400B2 (en) 2013-02-26 2017-02-28 Northeastern University Cannabinergic nitrate esters and related analogs
WO2014149207A2 (en) 2013-03-15 2014-09-25 Dow Agrosciences Llc Benzimidazole-based insecticidal compositions and related methods
JP5902641B2 (ja) 2013-03-27 2016-04-13 富士フイルム株式会社 光干渉顔料およびその製造方法
JP2014232188A (ja) 2013-05-29 2014-12-11 コニカミノルタ株式会社 セルロースアシレートフィルム、円偏光板及び画像表示装置
JP6387960B2 (ja) 2013-05-31 2018-09-12 コニカミノルタ株式会社 樹脂組成物、光学部材、光学フィルム、偏光板、円偏光板及び画像表示装置
WO2015030898A2 (en) 2013-06-07 2015-03-05 The Regents Of The University Of California Micromechanical resonant switches and charge pumps
EP3010512B1 (en) 2013-06-18 2017-12-27 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US20160145304A1 (en) 2013-07-12 2016-05-26 Helmholtz-Zentrum für Infektionsforschung GmbH Cystobactamides
CA2918365C (en) 2013-07-19 2021-09-07 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
JP2016529241A (ja) 2013-07-25 2016-09-23 フォンダッツィオーネ・テレソン Ｆａｐｐ２阻害剤及びそれらの使用
US20160168132A1 (en) 2013-07-31 2016-06-16 Minoryx Therapeutics S.L. Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof
KR101628288B1 (ko) 2013-09-30 2016-06-08 주식회사 엘지화학 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
SG11201604477SA (en) 2013-12-13 2016-07-28 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
US9204150B2 (en) 2014-02-26 2015-12-01 Intel Corporation Techniques for evaluating compressed motion video quality
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
WO2016022626A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
WO2016040449A1 (en) 2014-09-10 2016-03-17 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP2997966A1 (en) 2014-09-16 2016-03-23 Sanofi Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders
CN106317027A (zh) 2015-06-15 2017-01-11 山东轩竹医药科技有限公司 杂芳基酰胺类衍生物及其作为tgr5激动剂的应用
EP3350181B1 (en) 2015-09-02 2023-11-01 The Regents of The University of California Her3 ligands and uses thereof
US11413278B2 (en) 2015-10-08 2022-08-16 The Regents Of The University Of California Compounds and methods for promoting stress resistance
US20180305334A1 (en) 2015-10-14 2018-10-25 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
MX2018011105A (es) 2016-03-16 2018-11-22 Kura Oncology Inc Inhibidores sustituidos de menina-mll y metodos de uso.
KR20190063473A (ko) 2016-09-28 2019-06-07 블레이드 테라퓨틱스, 인크. 칼페인 조정자 및 그 치료학적 용도
EP3519533B1 (en) 2016-09-28 2020-12-16 Merck Patent GmbH Polymerisable liquid crystal material and polymerised liquid crystal film
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
WO2018195439A2 (en) 2017-04-20 2018-10-25 The Regents Of The University Of California K-ras modulators
WO2018202681A1 (en) 2017-05-04 2018-11-08 Bayer Cropscience Aktiengesellschaft Use of disubstituted benzenes to control insecticide-resistant pests
JP2019015998A (ja) 2017-07-03 2019-01-31 東芝テック株式会社 情報処理装置およびプログラム
JOP20200001A1 (ar) 2017-07-11 2022-10-30 Vertex Pharma كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI
WO2019036657A1 (en) 2017-08-17 2019-02-21 Kyn Therapeutics AHR INHIBITORS AND USES THEREOF
EP3746433A1 (en) 2018-01-30 2020-12-09 PI Industries Ltd. Novel anthranilamides, their use as insecticide and processes for preparing the same
EP3752152A1 (en) 2018-02-12 2020-12-23 Vertex Pharmaceuticals Incorporated A method of treating pain
WO2019207081A1 (en) 2018-04-27 2019-10-31 Merck Patent Gmbh Polymerisable liquid crystal material and polymerised liquid crystal film
CN112041413A (zh) 2018-04-27 2020-12-04 默克专利股份有限公司 可聚合的液晶材料和聚合的液晶膜
WO2019241787A1 (en) 2018-06-15 2019-12-19 The Regents Of The University Of Colorado A Body Corporate Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use
SG11202102208WA (en) 2018-09-04 2021-04-29 Magenta Therapeutics Inc Aryl hydrocarbon receptor antagonists and methods of use
WO2020081572A1 (en) 2018-10-15 2020-04-23 Dana-Farber Cancer Institute, Inc. Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof
EP3894392A4 (en) 2018-12-11 2022-08-24 Duke University COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
CA3124970A1 (en) 2018-12-28 2020-07-02 Cedars-Sinai Medical Center Methods of treating inflammatory bowel diseases that target ripk2
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
EP3914669B1 (en) 2019-01-22 2024-10-02 Merck Patent GmbH Method for the preparation of a liquid crystal polymer film
JP7473565B2 (ja) 2019-01-28 2024-04-23 ミトコンドリア エモーション， インク． マイトフュージン活性化物質及びその使用方法
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
CN113811300A (zh) 2019-03-15 2021-12-17 总医院公司 Tead转录因子的新型小分子抑制剂
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
WO2020221677A1 (en) 2019-04-30 2020-11-05 Merck Patent Gmbh Reactive mesogens
WO2020251974A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11866450B2 (en) 2018-02-15 2024-01-09 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
US11873300B2 (en) 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
US12122788B2 (en) 2023-01-04 2024-10-22 Vertex Pharmaceuticals Incorporated Process of making CFTR modulators

Also Published As

Publication number Publication date
TN2020000001A1 (en) 2021-10-04
DOP2020000004A (es) 2020-07-15
PE20201164A1 (es) 2020-10-28
CR20200064A (es) 2020-08-03
EP3651752A1 (en) 2020-05-20
MA49566A (fr) 2020-05-20
CA3069720A1 (en) 2019-01-17
CO2020000145A2 (es) 2020-01-17
US10647661B2 (en) 2020-05-12
JP7277431B2 (ja) 2023-05-19
KR20200026987A (ko) 2020-03-11
US20230286907A1 (en) 2023-09-14
TW201920081A (zh) 2019-06-01
BR112020000553A2 (pt) 2020-07-21
IL271948A (en) 2020-02-27
UY37806A (es) 2020-01-31
CL2020000075A1 (es) 2020-07-31
US20190016671A1 (en) 2019-01-17
US11603351B2 (en) 2023-03-14
PH12020500066A1 (en) 2020-09-28
JP2020526561A (ja) 2020-08-31
AU2018300150A1 (en) 2020-01-30
CN111065383A (zh) 2020-04-24
US20210094906A1 (en) 2021-04-01
WO2019014352A1 (en) 2019-01-17
SG11202000230VA (en) 2020-02-27
JOP20200001A1 (ar) 2022-10-30

Similar Documents

Publication Publication Date Title
ECSP20003147A (es) Carboxamidas como moduladores de los canales de sodio
UY38979A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CO2019013021A2 (es) Amidas de piridona deuteradas y sus profármacos como moduladores de los canales de sodio
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
UY35288A (es) Piridonamidas como moduladores de canales de sodio
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
PE20151427A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
CL2019003398A1 (es) Inhibidores pirazólicos de magl.
DOP2019000184A (es) Inhibidores selectivos de jak1
UY39800A (es) N–(hidroxialquil (hetero)aril) tetrahidrofuran carboxamidas como moduladores de canales de sodio
CO2017011017A2 (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CR20160047A (es) Inhibidores de rorc2 y sus métodos de uso
UY36322A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2019002583A1 (es) Inhibidores duales de magl y faah.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов
ECSP17025904A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos